Novo's Rybelsus CV results may not be clinically meaningful, Bernstein says
Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...
clinicaltrialsarena2d
Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral GLP-1R agonist, Rybelsus, ...
Novo Nordisk's Rybelsus Sets New Standard: 14% Cut in Cardiovascular Risks for Diabetics
SOUL Trial Results Position Rybelsus as a Game-Changer in Diabetes and Cardiovascular Care, Poised for Expanded U.S. and E.U.
Zacks.com on MSN3d
NVO's Rybelsus Meets Primary Goal in MACE Study for Diabetes Patients
A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...
FiercePharma4d
Novo plots US, EU approval filings after oral semaglutide shows cardio benefits in certain diabetes patients
As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...
Ozempic and other weight loss drugs aren't lowering health care costs yet
GLP-1 drugs like Wegovy (NVO) might help with weight loss, but they aren’t leading to lower health care costs yet, according ...
Becker's Hospital Review4h
3 recent Ozempic studies to know
Discover the latest research on Ozempic and other GLP-1 medications, including potential uses in treating Alzheimer's and opioid and alcohol use disorders.
BioSpace4d
Novo Scores Late-Stage CV Win for Rybelsus on Heels of Wegovy Label Expansion
Novo Nordisk on Monday reported the oral version of its drug semaglutide reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes by 14% in a large Phase III trial.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk's SOUL trial reveals a 14% reduction in major cardiovascular events with oral semaglutide in patients with type ...